Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines

Poly (ADP-ribose) polymerase (PARP)-inhibitors (PARPi) such as olaparib and niraparib are currently used as a treatment option for BRCA-deficient tumors and also show efficacy in platinum-sensitive tumors. However, resistance to PARPi occurs in numerous patients and in particular acquired PARPi resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fedier, André, Maggi, Nadia, Tozzi, Alessandra, Disler, Muriel, Coelho, Ricardo, Jacob, Francis, Heinzelmann-Schwarz, Viola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170353/
https://www.ncbi.nlm.nih.gov/pubmed/35642662
http://dx.doi.org/10.3892/ijo.2022.5379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170353/
https://www.ncbi.nlm.nih.gov/pubmed/35642662
http://dx.doi.org/10.3892/ijo.2022.5379

Ejemplares similares